Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kala Pharmaceuticals Inc (KALA)
NASDAQ:KALA
Holding KALA?
Track your performance easily
KALA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.21 - $9.25
Previous Close$5.92
Volume12.94K
Average Volume (3M)26.02K
Market Cap
$27.66M
Enterprise Value$15.50M
Total Cash (Recent Filing)$49.20M
Total Debt (Recent Filing)$37.04M
Price to Earnings (P/E)―
Beta-0.95
Next Earnings
Mar 27, 2025EPS Estimate
-$2.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.47
Shares Outstanding4,610,139
10 Day Avg. Volume32,358
30 Day Avg. Volume26,019
Standard Deviation0.85
R-Squared0.02
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)3.97
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$15.00Price Target Upside153.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Kala Pharmaceuticals News
PremiumCompany Announcements
Kala Bio Advances PCED Treatment Amid Financial Update
PremiumCompany Announcements
Kala Pharmaceuticals Board Member Mark Blumenkranz Resigns
Ownership Overview
18.57% Insiders
1.52% Mutual Funds
39.59% Other Institutional Investors
39.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
KALA FAQ
What was Kala Pharmaceuticals Inc’s price range in the past 12 months?
Kala Pharmaceuticals Inc lowest stock price was $4.21 and its highest was $9.25 in the past 12 months.
What is Kala Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Kala Pharmaceuticals Inc’s upcoming earnings report date?
Kala Pharmaceuticals Inc’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
How were Kala Pharmaceuticals Inc’s earnings last quarter?
Kala Pharmaceuticals Inc released its earnings results on Nov 12, 2024. The company reported -$1.93 earnings per share for the quarter, beating the consensus estimate of -$2.43 by $0.5.
Is Kala Pharmaceuticals Inc overvalued?
According to Wall Street analysts Kala Pharmaceuticals Inc’s price is currently Undervalued.
Does Kala Pharmaceuticals Inc pay dividends?
Kala Pharmaceuticals Inc does not currently pay dividends.
What is Kala Pharmaceuticals Inc’s EPS estimate?
Kala Pharmaceuticals Inc’s EPS estimate is -$2.28.
How many shares outstanding does Kala Pharmaceuticals Inc have?
Kala Pharmaceuticals Inc has 4,610,139 shares outstanding.
What happened to Kala Pharmaceuticals Inc’s price movement after its last earnings report?
Kala Pharmaceuticals Inc reported an EPS of -$1.93 in its last earnings report, beating expectations of -$2.43. Following the earnings report the stock price went down -4.189%.
Which hedge fund is a major shareholder of Kala Pharmaceuticals Inc?
Among the largest hedge funds holding Kala Pharmaceuticals Inc’s share is Baker Bros Advisors LP. It holds Kala Pharmaceuticals Inc’s shares valued at 5M.
---
Kala Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (153.38% Upside)
$15.00 (153.38% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.32%
12-Months-Change
Fundamentals
Return on Equity
-430.96%
Trailing 12-Months
Asset Growth
-11.52%
Trailing 12-Months
Company Description
Kala Pharmaceuticals Inc
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.
---
KALA Stock 12 Month Forecast
Average Price Target
$15.00
▲(153.38% Upside)
Technical Analysis
Best Analysts Covering KALA
1 Year
1 Year Success Rate
0/15 ratings generated profit
1 Year Average Return
-72.07%
assigned a buy rating 4 months ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -72.07% per trade.
---